It has already been successfully used to control inflammation in specific monogenic autoimmune diseases such as CTLA-4 or LRBA deficiency [3, 23, 24] and based on mode of activity is a valid candidate to control IPEX disease. The gene discussed is CTLA4; the disease is immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome.